A prolonged complete response in a patient with BRAF-mutated melanoma stage IV treated with the MEK1/2 inhibitor selumetinib (AZD6244)

Marye J Boers-Sonderen; Ingrid M Desar; Willeke Blokx; Johanna N Timmer-Bonte; Carla M van Herpen

doi:10.1097/CAD.0b013e328350737d

A prolonged complete response in a patient with BRAF-mutated melanoma stage IV treated with the MEK1/2 inhibitor selumetinib (AZD6244)

Marye J Boers-Sonderen
, Ingrid M Desar
, Willeke Blokx
, Johanna N Timmer-Bonte
, Carla M van Herpen

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

In melanoma, the RAS/RAF/MEK/ERK pathway is frequently activated by mutations in BRAF and NRAS. Selumetinib (AZD6244) is an oral, selective, non-ATP-competitive inhibitor of MEK1/2. Here, we describe a patient with metastatic melanoma (T1N2cM1a) with a BRAF V600E mutation. She is currently being treated with selumetinib 75 mg twice daily in a phase I trial and has shown complete response for the past 4 years. This case report raises questions regarding treatment schedule, treatment duration and management of adverse events.

Original language	English
Pages (from-to)	761-4
Number of pages	4
Journal	Anti-Cancer Drugs
Volume	23
Issue number	7
DOIs	https://doi.org/10.1097/CAD.0b013e328350737d
Publication status	Published - Aug 2012
Externally published	Yes

Keywords

Adult
Antineoplastic Agents/therapeutic use
Benzimidazoles/therapeutic use
Disease-Free Survival
Female
Head and Neck Neoplasms/drug therapy
Humans
MAP Kinase Kinase 1/antagonists & inhibitors
MAP Kinase Kinase 2/antagonists & inhibitors
Melanoma/drug therapy
Proto-Oncogene Proteins B-raf/genetics
Skin Neoplasms/drug therapy
Thoracic Neoplasms/drug therapy

Access to Document

10.1097/CAD.0b013e328350737d

Cite this

@article{a64735620e284d778d9e755c8f814846,

title = "A prolonged complete response in a patient with BRAF-mutated melanoma stage IV treated with the MEK1/2 inhibitor selumetinib (AZD6244)",

abstract = "In melanoma, the RAS/RAF/MEK/ERK pathway is frequently activated by mutations in BRAF and NRAS. Selumetinib (AZD6244) is an oral, selective, non-ATP-competitive inhibitor of MEK1/2. Here, we describe a patient with metastatic melanoma (T1N2cM1a) with a BRAF V600E mutation. She is currently being treated with selumetinib 75 mg twice daily in a phase I trial and has shown complete response for the past 4 years. This case report raises questions regarding treatment schedule, treatment duration and management of adverse events.",

keywords = "Adult, Antineoplastic Agents/therapeutic use, Benzimidazoles/therapeutic use, Disease-Free Survival, Female, Head and Neck Neoplasms/drug therapy, Humans, MAP Kinase Kinase 1/antagonists \& inhibitors, MAP Kinase Kinase 2/antagonists \& inhibitors, Melanoma/drug therapy, Proto-Oncogene Proteins B-raf/genetics, Skin Neoplasms/drug therapy, Thoracic Neoplasms/drug therapy",

author = "Boers-Sonderen, \{Marye J\} and Desar, \{Ingrid M\} and Willeke Blokx and Timmer-Bonte, \{Johanna N\} and \{van Herpen\}, \{Carla M\}",

year = "2012",

month = aug,

doi = "10.1097/CAD.0b013e328350737d",

language = "English",

volume = "23",

pages = "761--4",

journal = "Anti-Cancer Drugs",

issn = "0959-4973",

publisher = "Lippincott Williams \& Wilkins",

number = "7",

}

TY - JOUR

T1 - A prolonged complete response in a patient with BRAF-mutated melanoma stage IV treated with the MEK1/2 inhibitor selumetinib (AZD6244)

AU - Boers-Sonderen, Marye J

AU - Desar, Ingrid M

AU - Blokx, Willeke

AU - Timmer-Bonte, Johanna N

AU - van Herpen, Carla M

PY - 2012/8

Y1 - 2012/8

N2 - In melanoma, the RAS/RAF/MEK/ERK pathway is frequently activated by mutations in BRAF and NRAS. Selumetinib (AZD6244) is an oral, selective, non-ATP-competitive inhibitor of MEK1/2. Here, we describe a patient with metastatic melanoma (T1N2cM1a) with a BRAF V600E mutation. She is currently being treated with selumetinib 75 mg twice daily in a phase I trial and has shown complete response for the past 4 years. This case report raises questions regarding treatment schedule, treatment duration and management of adverse events.

AB - In melanoma, the RAS/RAF/MEK/ERK pathway is frequently activated by mutations in BRAF and NRAS. Selumetinib (AZD6244) is an oral, selective, non-ATP-competitive inhibitor of MEK1/2. Here, we describe a patient with metastatic melanoma (T1N2cM1a) with a BRAF V600E mutation. She is currently being treated with selumetinib 75 mg twice daily in a phase I trial and has shown complete response for the past 4 years. This case report raises questions regarding treatment schedule, treatment duration and management of adverse events.

KW - Adult

KW - Antineoplastic Agents/therapeutic use

KW - Benzimidazoles/therapeutic use

KW - Disease-Free Survival

KW - Female

KW - Head and Neck Neoplasms/drug therapy

KW - Humans

KW - MAP Kinase Kinase 1/antagonists & inhibitors

KW - MAP Kinase Kinase 2/antagonists & inhibitors

KW - Melanoma/drug therapy

KW - Proto-Oncogene Proteins B-raf/genetics

KW - Skin Neoplasms/drug therapy

KW - Thoracic Neoplasms/drug therapy

U2 - 10.1097/CAD.0b013e328350737d

DO - 10.1097/CAD.0b013e328350737d

M3 - Article

C2 - 22293660

SN - 0959-4973

VL - 23

SP - 761

EP - 764

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

IS - 7

ER -

A prolonged complete response in a patient with BRAF-mutated melanoma stage IV treated with the MEK1/2 inhibitor selumetinib (AZD6244)

Abstract

Keywords

Access to Document

Fingerprint

Cite this